Sensitization in Heart Transplantation: Emerging Knowledge
暂无分享,去创建一个
J. Kobashigawa | J. Lindenfeld | D. Tyan | Monica M. Colvin | Jennifer L. Cook | Daphne T. Hsu | Michael S. Kiernan | S. C. Masri | Dylan V. Miller | E. R. Rodriguez | Monica M Colvin | E. R. Rodriguez | Michael S. Kiernan
[1] B. Levin,et al. Ventricular assist device elicits serum natural IgG that correlates with the development of primary graft dysfunction following heart transplantation. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[2] D. Mancini,et al. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[3] J. Kobashigawa,et al. Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[4] A. Zeevi,et al. Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes , 2017, Front. Immunol..
[5] A. Israni,et al. OPTN/SRTR 2015 Annual Data Report: Heart , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[6] G. Berry,et al. The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody‐Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[7] Jean Kanitakis,et al. An integrated view of immune monitoring in vascularized composite allotransplantation , 2016, Current opinion in organ transplantation.
[8] Gordon D. Wu,et al. Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. , 2016, Transplant immunology.
[9] J. Patel,et al. Desensitization strategies in adult heart transplantation-Will persistence pay off? , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[10] P. Rowe,et al. A reliable method for avoiding false negative results with Luminex single antigen beads; evidence of the prozone effect. , 2016, Transplant immunology.
[11] G. Ghiggeri,et al. Acquisition of C3d‐Binding Activity by De Novo Donor‐Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] P. Oyer,et al. Influence of durable mechanical circulatory support and allosensitization on mortality after heart transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] A. Ducharme,et al. Multicenter evaluation of a national organ sharing policy for highly sensitized patients listed for heart transplantation in Canada. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[14] D. Mancini,et al. The Impact of Donor Specific Antibodies on Antibody Mediated Rejection , 2016 .
[15] J. Patel,et al. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[16] L. Rostaing,et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.
[17] X. Jouven,et al. Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody‐Mediated Rejection , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[18] P S Heeger,et al. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation‐05 Study , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] J. Kautzner,et al. Novel insights into pretransplant allosensitization in heart transplant recipients in the contemporary era of immunosuppression and rejection surveillance , 2016, Transplant international : official journal of the European Society for Organ Transplantation.
[20] B. Chung,et al. Increase of Th17 Cell Phenotype in Kidney Transplant Recipients with Chronic Allograft Dysfunction , 2015, PloS one.
[21] N. Maillard,et al. Protein A-Based Immunoadsorption Is More Efficient Than Conventional Plasma Exchange to Remove Circulating Anti-HLA Antibodies , 2015, Blood Purification.
[22] V. Rao,et al. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[23] C. Hunter,et al. IL-6 as a keystone cytokine in health and disease , 2015, Nature Immunology.
[24] R. Shemin,et al. Characterization of ventricular assist device-mediated sensitization in the bridge-to-heart-transplantation patient. , 2015, The Journal of thoracic and cardiovascular surgery.
[25] M. Cascalho,et al. Efficacy of plasmapheresis on donor‐specific antibody reduction by HLA specificity in post–kidney transplant recipients , 2015, Transfusion.
[26] G. Klintmalm,et al. Impact of IgG3 Subclass and C1q‐Fixing Donor‐Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] G. Baron,et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. , 2015, Annals of the rheumatic diseases.
[28] M. Haas,et al. A Phase I/II Placebo-Controlled Trial of C1-Inhibitor for Prevention of Antibody-Mediated Rejection in HLA Sensitized Patients , 2015, Transplantation.
[29] R. Alloway,et al. Prospective Iterative Trial of Proteasome Inhibitor‐Based Desensitization , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] R. Montgomery,et al. Differential Effect of Bortezomib on HLA Class I and Class II Antibody , 2014, Transplantation.
[31] S. Schaub,et al. Determinants of C1q Binding in the Single Antigen Bead Assay , 2014, Transplantation.
[32] M. Haas,et al. Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients , 2014, Transplantation.
[33] V. Thohan,et al. Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[34] C. Ensor,et al. Carfilzomib for Refractory Antibody Mediated Rejection and Allosensitization in Heart Transplantation , 2014 .
[35] J. Pascual,et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? , 2013, Transplant immunology.
[36] N. Smedira,et al. HLA and MICA allosensitization patterns among patients supported by ventricular assist devices. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[37] X. Jouven,et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.
[38] M. Clatworthy,et al. Elevated Pretransplantation Soluble BAFF Is Associated With an Increased Risk of Acute Antibody-Mediated Rejection , 2013, Transplantation.
[39] W. Kremers,et al. LVAD Implant as a Bridge to Heart Transplantation Is Associated with Allosensitization as Measured by Single Antigen Bead Assay , 2013, Transplantation.
[40] F. Fallani,et al. Occurrence of Fatal and Nonfatal Adverse Outcomes after Heart Transplantation in Patients with Pretransplant Noncytotoxic HLA Antibodies , 2013, Journal of transplantation.
[41] M. Neurath,et al. How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy , 2013, Nature Medicine.
[42] Mark E. Williams,et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.
[43] C. Haisch,et al. The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes , 2013, Transplantation.
[44] D. Monos,et al. Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[45] R. Rodeheffer,et al. Donor-Specific Antibodies to Class II Antigens Are Associated With Accelerated Cardiac Allograft Vasculopathy: A Three-Dimensional Volumetric Intravascular Ultrasound Study , 2013, Transplantation.
[46] A. Webster,et al. Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation , 2013, Transplantation.
[47] J. Pirk,et al. Alloimmunosensitization in left ventricular assist device recipients and impact on posttransplantation outcome. , 2012, ASAIO journal.
[48] A. Minguela,et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. , 2012, Transplantation proceedings.
[49] G. Klintmalm,et al. Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[50] D. Barz,et al. Plasma Exchange and Immunoadsorption of Patients with Thoracic Organ Transplantation , 2012, Transfusion Medicine and Hemotherapy.
[51] J. Kobashigawa,et al. The use of the calculated panel-reactive antibody and virtual crossmatch in heart transplantation , 2012, Current opinion in organ transplantation.
[52] S. Jordan,et al. Evolving paradigms for desensitization in managing broadly HLA sensitized transplant candidates. , 2012, Discovery medicine.
[53] N. Banner,et al. Late Antibody-Mediated Rejection After Heart Transplantation Following the Development of De Novo Donor-Specific Human Leukocyte Antigen Antibody , 2012, Transplantation.
[54] J. Pober,et al. Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells , 2011, The Journal of Immunology.
[55] E. Reed,et al. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[56] M. Stegall,et al. Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[57] S. Russell,et al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. , 2011, The Journal of thoracic and cardiovascular surgery.
[58] V. Valentine,et al. Transplantation of high panel-reactive antibody left ventricular assist device patients without crossmatch using on-bypass pheresis and alemtuzumab. , 2011, The Annals of thoracic surgery.
[59] D. Tyan,et al. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.
[60] A. Ender,et al. HLA Antibody Specification Using Single-Antigen Beads—A Technical Solution for the Prozone Effect , 2011, Transplantation.
[61] C. Marboe,et al. HLA antibodies in pediatric heart transplantation , 2011, Pediatric transplantation.
[62] L. Kucirka,et al. Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.
[63] X. Jouven,et al. Very Late Heart Transplant Rejection Is Associated with Microvascular Injury, Complement Deposition and Progression to Cardiac Allograft Vasculopathy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[64] J. Cecka,et al. Calculated PRA: Initial Results Show Benefits for Sensitized Patients and a Reduction in Positive Crossmatches , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[65] M. Petri,et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[66] N. Banner,et al. De Novo Donor HLA‐Specific Antibodies after Heart Transplantation Are an Independent Predictor of Poor Patient Survival , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[67] G. Berry,et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[68] Ronny Gustafsson,et al. Desensitization and Heart Transplantation of a Patient With High Levels of Donor-Reactive Anti-Human Leukocyte Antigen Antibodies , 2010, Transplantation.
[69] G. Gupta,et al. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation , 2010, Drug design, development and therapy.
[70] R. Starling,et al. Management of the sensitized adult heart transplant candidate , 2010, Clinical transplantation.
[71] A. Amodeo,et al. Pneumatic pulsatile ventricular assist device as a bridge to heart transplantation in pediatric patients. , 2010, Artificial organs.
[72] A. Rahmel,et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report--2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[73] W. Dreyer,et al. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. , 2010, The Journal of thoracic and cardiovascular surgery.
[74] Clive Lewis,et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[75] S. Webber,et al. Immunosuppression Therapy for Pediatric Heart Transplantation , 2010, Current treatment options in cardiovascular medicine.
[76] A. Amodeo,et al. Mechanical assist device as a bridge to heart transplantation in children less than 10 kilograms. , 2010, The Annals of thoracic surgery.
[77] S. Jordan,et al. Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation , 2010, Transplantation.
[78] N. Pallet,et al. Bortezomib as the Sole Post‐Renal Transplantation Desensitization Agent Does Not Decrease Donor‐Specific Anti‐HLA Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[79] E. Reed,et al. 307: The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized Heart Transplant Candidates: Does It Make Sense To Desensitize? , 2010 .
[80] W. Hop,et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome , 2009, Annals of neurology.
[81] Maryl R. Johnson,et al. Management of allosensitized cardiac transplant candidates. , 2009, Transplantation reviews.
[82] D. Mancini,et al. Alloantibodies in heart transplantation. , 2009, Human immunology.
[83] J. Platt,et al. The role of antibodies in transplantation. , 2009, Transplantation reviews.
[84] M. Daha,et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. , 2009, Kidney international.
[85] J. Bradley,et al. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. , 2009, Human immunology.
[86] B. Horne,et al. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[87] M. Rose,et al. Clinical relevance of complement-fixing antibodies in cardiac transplantation. , 2009, Human immunology.
[88] Junchao Cai,et al. Intact HLA Not &bgr;2m-free Heavy Chain-Specific HLA Class I Antibodies Are Predictive of Graft Failure , 2009, Transplantation.
[89] Kirk R. Kanter,et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. , 2009, Journal of the American College of Cardiology.
[90] P. Terasaki,et al. Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2009, Transplantation.
[91] R. Holdsworth,et al. Review article: Luminex technology for HLA antibody detection in organ transplantation , 2009, Nephrology.
[92] E. Reed,et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[93] Jie Zheng,et al. Decline in rejection in the first year after pediatric cardiac transplantation: a multi-institutional study. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[94] R. Gajarski,et al. HLA sensitization in pediatric pre-transplant cardiac patients supported by mechanical assist devices: the utility of Luminex. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[95] R. Alloway,et al. Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.
[96] M. Stegall,et al. Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[97] J. Friedewald,et al. Tailoring Antibody Testing and How to Use it in the Calculated Panel Reactive Antibody Era: The Northwestern University Experience , 2008, Transplantation.
[98] C. Canter,et al. Biventricular Assist Devices as a Bridge to Heart Transplantation in Small Children , 2008, Circulation.
[99] Susan Martin,et al. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. , 2008, Transplantation.
[100] S. Jordan,et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.
[101] M. Oz,et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. , 2008, The Journal of thoracic and cardiovascular surgery.
[102] J. Friedewald,et al. Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[103] S. Vaidya. Clinical Importance of Anti-Human Leukocyte Antigen-Specific Antibody Concentration in Performing Calculated Panel Reactive Antibody and Virtual Crossmatches , 2008, Transplantation.
[104] N. Banner,et al. C4d Fixing, Luminex Binding Antibodies—A New Tool for Prediction of Graft Failure After Heart Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[105] S. Russell,et al. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. , 2007, The Annals of thoracic surgery.
[106] M. Hibi,et al. The molecular biology of interleukin 6 and its receptor. , 2007, Ciba Foundation symposium.
[107] S. Boslaugh,et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[108] S. Webber,et al. Survival in allosensitized children after listing for cardiac transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[109] B. Meiser,et al. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[110] P. Terasaki,et al. The Importance of Anti‐HLA‐Specific Antibody Strength in Monitoring Kidney Transplant Patients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[111] J. Kirklin,et al. Cardiac re-transplantation in pediatrics: a multi-institutional study. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[112] S. Chu,et al. Effect of plasmapheresis for acute humoral rejection after heart transplantation. , 2006, Transplantation proceedings.
[113] J. Wald,et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin , 2006, Clinical transplantation.
[114] A. Keren,et al. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab. , 2006, Transplantation proceedings.
[115] M. Fishbein,et al. Acute antibody-mediated rejection of cardiac transplants. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[116] A. Castro‐Beiras,et al. Humoral Heart Rejection (Severe Allograft Dysfunction with no Signs of Cellular Rejection or Ischemia): Incidence, Management, and the Value of C4d for Diagnosis , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[117] S. Mital,et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[118] R. Graff,et al. Use of rituximab to decrease panel-reactive antibodies. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[119] J. Fallon,et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. , 2004, Transplantation proceedings.
[120] D. Stablein,et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.
[121] J. Jacobs,et al. Pediatric cardiac transplantation in children with high panel reactive antibody. , 2004, The Annals of thoracic surgery.
[122] P. Nickerson,et al. National Conference to Assess Antibody‐Mediated Rejection in Solid Organ Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[123] G. Opelz,et al. SKEWING OF PRETRANSPLANT ANTI-HLA CLASS I ANTIBODIES OF IMMUNOGLOBULIN G ISOTYPE SOLELY TOWARD IMMUNOGLOBULIN G1 SUBCLASS IS ASSOCIATED WITH POORER RENAL ALLOGRAFT SURVIVAL , 2004, Transplantation.
[124] N. Reinsmoen,et al. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. , 2004, Transplant immunology.
[125] C. Hillyer,et al. Unappreciated risk factors for transplant patients: HLA antibodies in blood components. , 2004, Human immunology.
[126] N. Fineberg,et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics1 , 2004, Transplantation.
[127] J. Patel,et al. The highly sensitized patient awaiting heart transplantation: success with combination therapy of plasmapheresis and intravenous gamma globulin , 2004 .
[128] Mitchell R. Smith. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.
[129] Bart Barlogie,et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.
[130] H. Eisen,et al. Cardiac transplantation across a positive prospective lymphocyte cross‐match in sensitized recipients , 2003, Clinical transplantation.
[131] C. Cunningham-Rundles,et al. Utility of Intravenous Immune Globulin in Kidney Transplantation: Efficacy, Safety, and Cost Implications , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[132] M. Mehra,et al. Allosensitization in heart transplantation: implications and management strategies , 2003, Current opinion in cardiology.
[133] R. Duquesnoy,et al. Multilaboratory evaluation of serum analysis for HLA antibody and crossmatch reactivity by lymphocytotoxicity methods. , 2003, Archives of pathology & laboratory medicine.
[134] P. Terasaki,et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities , 2003, Transplantation.
[135] M. Dalakas. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies , 2002, Neurology.
[136] M. Welters,et al. A broad and strong humoral immune response to donor HLA after implantation of cryopreserved human heart valve allografts. , 2002, Human immunology.
[137] K. Groshart,et al. Treatment of humoral rejection with rituximab. , 2002, The Annals of thoracic surgery.
[138] H. Hashimoto,et al. Plasma adsorption in critical care. , 2002, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[139] J. Aranda,et al. Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. , 2002, Transplantation.
[140] E. Gelfand. Antibody-directed therapy: past, present, and future. , 2001, The Journal of allergy and clinical immunology.
[141] D. Mancini,et al. Increased Prevalence of Autoimmune Phenomena and Greater Risk for Alloreactivity in Female Heart Transplant Recipients , 2001, Circulation.
[142] S. Kaveri,et al. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.
[143] A. Zachary,et al. Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance. , 2001, Human immunology.
[144] R. Hetzer,et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[145] S. Takemoto,et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. , 2000, Transplantation.
[146] H. Hagberg,et al. Risk factors for side effects during first infusion of rituximab—definition of a low risk group , 2000, Medical oncology.
[147] R. Bray,et al. Sensitization and sensitivity: defining the unsensitized patient. , 2000, Transplantation.
[148] L. Lambert,et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. , 2000, The Journal of thoracic and cardiovascular surgery.
[149] P. Terasaki,et al. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. , 1999, Human immunology.
[150] M. Oz,et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. , 1999, Circulation.
[151] O. Press,et al. Clinical applications of anti-CD20 antibodies. , 1999, The Journal of laboratory and clinical medicine.
[152] J. A. Robinson,et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[153] M. Oz,et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. , 1998, Circulation.
[154] N. Smedira,et al. Vascular rejection post heart transplantation is associated with positive flow cytometric cross-matching. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[155] D. Reichenbach,et al. The clinical significance of flow cytometry crossmatching in heart transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[156] R. Dowling,et al. Use of intravenous immunoglobulin in sensitized LVAD recipients. , 1998, Transplantation proceedings.
[157] E. Reed,et al. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. , 1997, Journal of immunology.
[158] N G Smedira,et al. Factors influencing HLA sensitization in implantable LVAD recipients. , 1997, The Annals of thoracic surgery.
[159] J. Kobashigawa,et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? , 1996, Circulation.
[160] L. Lambert,et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. , 1996, Circulation.
[161] E. Reed,et al. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant-associated coronary artery disease. , 1996, Transplantation.
[162] G. Couper,et al. Role of panel-reactive antibody cross-reactivity in predicting survival after orthotopic heart transplantation. , 1994, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[163] D. Renlund,et al. OUTCOME OF CARDIAC TRANSPLANT RECIPIENTS WITH A POSITIVE DONOR‐SPECIFIC CROSSMATCH—PRELIMINARY RESULTS WITH PLASMAPHERESIS , 1992, Transplantation.
[164] J. Dwyer. Manipulating the immune system with immune globulin. , 1992, The New England journal of medicine.
[165] B. Griffith,et al. Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[166] C. Marboe,et al. The role of anti-HLA antibodies in heart transplantation. , 1991, Transplantation.
[167] J. Himmelfarb,et al. Extracorporeal removal of anti-HLA antibodies in transplant candidates. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[168] P. Terasaki,et al. Significance of the positive crossmatch test in kidney transplantation. , 1969, The New England journal of medicine.
[169] T. Edgington,et al. HUMAN BLOOD LYMPHOCTYE CYTOTOXICITY REACTIONS WITH ALLOGENIC ANTISERA * , 1964, Annals of the New York Academy of Sciences.
[170] Mark Payne,et al. Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.
[171] X. Jouven,et al. IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. , 2016, Journal of the American Society of Nephrology : JASN.
[172] E. Reed,et al. Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. , 2013, Methods in molecular biology.
[173] J. Lunz,et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[174] R. Bray. Lymphocyte crossmatching by flow cytometry. , 2013, Methods in molecular biology.
[175] R. Bray,et al. Clinical cytometry and progress in HLA antibody detection. , 2011, Methods in cell biology.
[176] E. Reed,et al. The long‐term outcome of treated sensitized patients who undergo heart transplantation , 2011, Clinical transplantation.
[177] D. Mancini,et al. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. , 2011, Human immunology.
[178] J. Pirsch,et al. Antibody-mediated rejection: treatment alternatives and outcomes. , 2009, Transplantation reviews.
[179] R. Alloway,et al. Proteasome inhibition reduces donor-specific antibody levels. , 2009, Transplantation proceedings.
[180] M. Fishbein,et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[181] A. Davis. Structure and function of C1 inhibitor. , 1989, Behring Institute Mitteilungen.
[182] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.